Please join us for a meeting

The First and Only Dual-Pathway-Inhibiting Therapy in nAMD and DME

Friday, May 13, 2022

1:00 PM ET

Louisville Marriott East,

Bluegrass AB Ballroom

1903 Embassy Square Blvd

Louisville, KY 40299

Join John Kitchens MD to learn more about VABYSMO (faricimab-svoa) injection, the first dual-pathway-inhibiting therapy designed to target Ang-2 and VEGF-A for the treatment of patients with nAMD or DME.

To register for this event, please visit genentechrsvp.com and enter CM42735.

VABYSMO

John Kitchens, MD
MD
Retina Associates of Kentucky

DME = diabetic macular edema;
nAMD = neovascular age-related macular degeneration

Indications

VABYSMO (faricimab-svoa) is vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

Important Safety Information

Contraindications

VABYSMO is contraindicated in patients with ocular or periocular inflammation, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO.

Warnings and Precautions

- Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management.
- Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.
- There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition.

Please see the accompanying VABYSMO full Prescribing Information and additional Important Safety Information on the next page.

Genentech
A Member of the Roche Group

©2022 Genentech USA, Inc. All rights reserved. M-US-00014205(v2.0) 02/22

VABYSMO™
faricimab-svoa injection 6 mg

Important Safety Information (continued)

Adverse Reactions

The most common adverse reaction (≥5%) reported in patients receiving VABYSMO was conjunctival hemorrhage (7%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the VABYSMO full Prescribing Information and additional Important Safety Information on the previous page.

This event is sponsored by Genentech USA, Inc. No continuing education credits are offered with this program.

Minnesota, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.
When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program.
If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program.
For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).
The meal value reported may vary by event location and be up to $150 per person (exceptions may apply).

Genentech
A Member of the Roche Group

VABYSMO™
faricimab-svoa injection 6 mg

©2022 Genentech USA, Inc. All rights reserved. M-US-00014205(v2.0) 02/22